3rd Circ. Will Decide Lipitor, Effexor Pay-For-Delay Suits

By Eric Kroh (April 13, 2017, 2:35 PM EDT) -- The Third Circuit on Thursday said it has jurisdiction to consider the merits of two appeals of lower court dismissals of alleged pay-for-delay litigation over the drugs Lipitor and Effexor XR, rejecting calls by the pharmaceutical companies involved in the cases to transfer them to the Federal Circuit.

Wyeth Inc. and Teva Pharmaceutical Industries Ltd. — the defendants in the Effexor case — and Pfizer Inc. and Ranbaxy Laboratories Inc. — which were sued in the Lipitor case — had argued that the Federal Circuit should hear the cases because it has exclusive jurisdiction over matters arising under patent law, but...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!